Research
Akkermansia muciniphila
7 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review.
Systematic review of 13 studies on Akkermansia muciniphila in preclinical mouse models of NAFLD. A. muciniphila reduced body weight, hepatic steatosis, and serum lipid levels, improved insulin sensitivity, and decreased liver enzyme levels. It also enhanced gut barrier function and exhibited anti-inflammatory effects.
Akkermansia muciniphila and Alcohol-Related Liver Diseases. A Systematic Review.
Systematic review on Akkermansia muciniphila, focusing on its bacteriological characteristics, factors modulating its abundance, and its probiotic use in alcohol-related liver diseases. Supplementation with A. muciniphila can improve ethanol-related hepatic pathologies.
Comparing the effects of yogurt containing Akkermansia muciniphilia postbiotic with yogurt containing Lactobacillus rhamnosus postbiotic on body composition, biochemical indices, appetite, and depression scores in overweight or obese adults: A randomized, double-blind, controlled clinical trial.
This 8-week randomized double-blind clinical trial compared the effects of yogurt containing Akkermansia muciniphila postbiotic with yogurt containing Lactobacillus rhamnosus postbiotic on health parameters in overweight and obese adults. The Akkermansia muciniphila group showed significant reductions in waist circumference, waist-to-height ratio, body fat percentage, aspartate aminotransferase levels, and appetite scores compared to the control group, while the Lactobacillus rhamnosus group did not show beneficial impacts.
Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut.
A 12-week randomized, double-blind, placebo-controlled trial with 58 overweight or obese T2D patients assessed the effects of Akkermansia muciniphila supplementation. While both groups showed decreases in body weight and HbA1c, significant improvements were observed in participants with low baseline A. muciniphila levels, indicating that efficacy may depend on initial gut levels.
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.
This randomized, double-blind, placebo-controlled pilot study investigated the effects of daily oral supplementation of Akkermansia muciniphila in overweight/obese insulin-resistant volunteers. The study found that pasteurized A. muciniphila improved insulin sensitivity, reduced insulinemia and plasma total cholesterol, and slightly decreased body weight and fat mass compared to placebo. The intervention was safe and well tolerated, improving several metabolic parameters.
Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.
RCT evaluating the association between faecal Akkermansia muciniphila abundance and metabolic health during a dietary intervention in overweight and obese adults. Higher A. muciniphila abundance was linked to healthier metabolic status and better clinical outcomes after calorie restriction.
Akkermansia muciniphila Alleviates Dextran Sulfate Sodium (DSS)-Induced Acute Colitis by NLRP3 Activation
The study investigates the effect of Akkermansia muciniphila on DSS-induced acute colitis in mice. Oral administration of A. muciniphila strain BAA-835 significantly ameliorated colitis symptoms, with decreased body weight loss, colon length shortening, and inflammatory scores. The protective effect was linked to NLRP3 activation.